查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1566840

阿米巴細胞裂解物市場：按類型、按應用：2024-2033 年全球機會分析與產業預測

Amebocyte Lysate Market By Type (Limulus Amebocyte Lysate, Tachypleus Amebocyte Lysate) , By Application (Drug Testing, Clinical Diagnosis, Other) : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

阿米巴細胞裂解液市場

2023年阿米巴細胞裂解物市值為6億美元，預計2024年至2033年複合年成長率為11.8%，2033年達到19億美元。

變形細胞裂解物從鱟血細胞或變形細胞中獲得，以其在細菌內毒素存在下獨特的凝血特性而聞名。阿米巴裂解物是生物醫學研究和製藥領域的重要組成部分，特別是用於細菌內毒素的檢測。由於其出色的靈敏度，阿米巴細胞裂解物可用於環境監測，特別是用於水和其他環境樣品的細菌污染的品質評估。

藥物測試領域是阿米巴細胞裂解物市場的關鍵驅動力。變形細胞裂解物和邊緣變形細胞裂解物 (LAL) 測試用於藥物開發的藥物測試的多個階段，包括原料測試、進程內測試和最終產品測試。最近，重組 DNA 技術已趨向於利用變形蟲細胞裂解物的特性進行各種應用。該技術開發了阿米巴細胞裂解物遺傳成分的副本，並已證明其具有可擴展性、一致性和減少對鱟種群的依賴等優勢。

然而，遵守每個國家頒布的藥典法規對於市場相關人員來說是一項複雜且成本高昂的挑戰，阻礙了市場成長。此外，有關在測試中使用動物以及用於生產阿米巴細胞裂解物的自然資源的永續性的倫理考慮正在阻礙市場開拓。為了解決這些問題，研究發現組織 AmeboGenesis(TM) 推出了一種永續的變形蟲細胞生產方法。這是一種創新方法，採用永續的方法，收穫鱟腿肌肉，進行培養，並使用全能幹細胞分化為變形蟲細胞。該過程極大地控制了變形蟲細胞的產生，並確保了穩定的鱟試劑濃度和產量。這種方法每年阻止約 80 萬隻鱟的捕獲和放血，捕獲後的存活率非常低。

板塊回顧

阿米巴細胞裂解物市場分為類型、應用和區域。依類型分為邊緣阿米巴細胞裂解物和胸腺阿米巴細胞裂解物。依應用範圍分為藥物檢測、臨床診斷等。從區域來看，分析涵蓋北美、歐洲、亞太地區和拉丁美洲/中東/非洲。

主要發現

按類型分類，邊緣變形細胞裂解物細分市場是 2023 年的主要股東。

從應用來看，藥物檢測領域在 2023 年佔據了主要佔有率。

預計到 2033 年，亞太地區阿米巴細胞裂解物市場將快速成長。

該報告可以客製化（需要單獨的費用和時間表）。

  • 監管指引
  • 根據客戶興趣加入公司簡介
  • 按國家或地區進行的附加分析 – 市場規模和預測
  • 擴大公司簡介列表
  • 主要參與企業的詳細資料（Excel格式，包括位置、聯絡資訊、供應商/供應商網路等）

目錄

第1章簡介

第 2 章執行摘要

第3章 市場狀況

  • 市場定義和範圍
  • 主要發現
    • 關鍵投資機會
    • 關鍵成功策略
  • 波特五力分析
  • 市場動態
    • 促進因素
    • 抑制因素
    • 機會

第4章 變形細胞裂解物市場：依類型

  • 市場概況
  • 邊緣阿米巴細胞裂解物
  • 胸腺變形細胞裂解物

第5章 變形細胞裂解物市場：依應用分類

  • 市場概況
  • 藥物測試
  • 臨床診斷
  • 其他

第6章阿米巴細胞裂解物市場：按地區

  • 市場概況
  • 北美洲
    • 主要市場趨勢和機遇
    • 美國阿米巴細胞裂解液市場
    • 加拿大阿米巴細胞裂解液市場
    • 墨西哥阿米巴細胞裂解液市場
  • 歐洲
    • 主要市場趨勢和機遇
    • 德國阿米巴細胞裂解液市場
    • 法國阿米巴細胞裂解液市場
    • 英國阿米巴細胞裂解液市場
    • 義大利阿米巴細胞裂解液市場
    • 西班牙阿米巴細胞裂解液市場
    • 其他歐洲阿米巴細胞裂解物市場
  • 亞太地區
    • 主要市場趨勢和機遇
    • 日本阿米巴細胞裂解液市場
    • 中國阿米巴細胞裂解液市場
    • 澳洲阿米巴細胞裂解液市場
    • 印度阿米巴細胞裂解液市場
    • 韓國阿米巴細胞裂解液市場
    • 其他亞太變形細胞裂解物市場
  • 拉丁美洲/中東/非洲
    • 主要市場趨勢和機遇
    • 巴西阿米巴細胞裂解液市場
    • 沙烏地阿拉伯變形細胞裂解物市場
    • 南非阿米巴細胞裂解液市場
    • 其他拉丁美洲/中東/非洲阿米巴細胞裂解物市場

第7章 競爭狀況

  • 介紹
  • 關鍵成功策略
  • 10家主要企業產品圖譜
  • 有競爭力的儀表板
  • 競爭熱圖
  • 主要企業定位（2023年）

第8章 公司簡介

  • Lonza Group AG
  • Charles River Laboratories
  • Associates of Cape Cod Inc
  • Xiamen Bioendo Technology
  • Zhanjiang A&C Biological
  • Genscript Technology Corporation
  • Nelson Laboratories, LLC
  • Thermo Fisher Scientific, Inc.
  • Merck And Co., Inc.
  • Microcoat Biotechnologie GmbH
簡介目錄
Product Code: A65445

Amebocyte Lysate Market

The amebocyte lysate market was valued at $0.6 billion in 2023 and is projected to reach $1.9 billion by 2033, growing at a CAGR of 11.8% from 2024 to 2033.

Amebocyte lysate, derived from the blood cells or amebocytes of horseshoe crabs, is well-known for its unique property of clotting in the presence of bacterial endotoxins. It is a crucial component in the field of biomedical research & pharmaceuticals and is particularly utilized for the detection of bacterial endotoxins. Due to its exceptional sensitivity, amebocyte lysate is used in environmental monitoring, particularly for the assessment of quality of water and other environmental samples for bacterial contamination.

The field of drug testing is a significant driver of the amebocyte lysate market. Several stages of drug testing such as raw material testing, in-process testing, and final product testing make use of amebocyte lysate and limulus amebocyte lysate (LAL) test for pharmaceutical development. In recent times, recombinant DNA technology is trending for the utilization of properties of amebocyte lysate in different applications. Ther technology develops copies of the genetic components of amebocyte lysate and offers benefits such as scalability, consistency, & reduced reliance on horseshoe crab populations.

However, compliance with the pharmacopeial regulations established in different countries is a complex and expensive challenge for the market players which prevents the growth of the market. In addition, the ethical considerations regarding the usage of animals in testing and the sustainability of natural resources used in amebocyte lysate production hinder market development. To combat such issues, AmeboGenesis(TM), a research and discovery organization, introduced a sustainable way of production of amebocytes. This is an innovative method which utilizes a sustainable approach involving the reaping of leg muscles of a horseshoe crab, culturing, and differentiating them into amebocytes by the use of totipotent stem cells. This process ensures a significant control over amebocyte production, along with consistent LAL concentration & production. This approach prevents the annual harvest and bleeding of approximately 800,000 horseshoe crabs, with a notably low survival rate post-harvesting.

Segment Review

The amebocyte lysate market is segmented into type, application, and region. By type, the market is bifurcated into limulus amebocyte lysate and tachypleus amebocyte lysate. On the basis of application, it is divided into drug testing, clinical diagnosis, and others. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

By type, the limulus amebocyte lysate segment was the major shareholder in 2023.

Depending on application, the drug testing segment garnered a major share in 2023.

The amebocyte lysate market is expected to experience rapid growth In Asia Pacific by 2033.

Competition Analysis

The major players operating in the global amebocyte lysate market include Lonza Group AG, Charles River Laboratories, Associates Of Cape Cod, Xiamen Bioendo Technology, Zhanjiang A&c Biological, GenScript, Nelson Laboratories, LLC, Thermo Fisher Scientific, Inc., Merck & Co, and Microcoat Biotechnologie GmbH. These players have adopted various key developmental strategies such as business expansion, new product launches, and partnerships to strengthen their foothold in the market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Regulatory Guidelines
  • Additional company profiles with specific to client's interest
  • Additional country or region analysis- market size and forecast
  • Expanded list for Company Profiles
  • Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Type

  • Limulus Amebocyte Lysate
  • Tachypleus Amebocyte Lysate

By Application

  • Drug Testing
  • Clinical Diagnosis
  • Other

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • France
    • UK
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • South Africa
    • Rest of LAMEA

Key Market Players:

    • Lonza Group AG
    • Charles River Laboratories
    • Associates of Cape Cod Inc
    • Xiamen Bioendo Technology
    • Zhanjiang A&C Biological
    • Genscript Technology Corporation
    • Nelson Laboratories, LLC
    • Thermo Fisher Scientific, Inc.
    • Merck & Co., Inc.
    • Microcoat Biotechnologie GmbH

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: AMEBOCYTE LYSATE MARKET, BY TYPE

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Type
  • 4.2. Limulus Amebocyte Lysate
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Tachypleus Amebocyte Lysate
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: AMEBOCYTE LYSATE MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Drug Testing
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Clinical Diagnosis
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Other
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: AMEBOCYTE LYSATE MARKET, BY REGION

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Region
  • 6.2. North America
    • 6.2.1. Key Market Trends and Opportunities
    • 6.2.2. Market Size and Forecast, By Type
    • 6.2.3. Market Size and Forecast, By Application
    • 6.2.4. Market Size and Forecast, By Country
    • 6.2.5. U.S. Amebocyte Lysate Market
      • 6.2.5.1. Market Size and Forecast, By Type
      • 6.2.5.2. Market Size and Forecast, By Application
    • 6.2.6. Canada Amebocyte Lysate Market
      • 6.2.6.1. Market Size and Forecast, By Type
      • 6.2.6.2. Market Size and Forecast, By Application
    • 6.2.7. Mexico Amebocyte Lysate Market
      • 6.2.7.1. Market Size and Forecast, By Type
      • 6.2.7.2. Market Size and Forecast, By Application
  • 6.3. Europe
    • 6.3.1. Key Market Trends and Opportunities
    • 6.3.2. Market Size and Forecast, By Type
    • 6.3.3. Market Size and Forecast, By Application
    • 6.3.4. Market Size and Forecast, By Country
    • 6.3.5. Germany Amebocyte Lysate Market
      • 6.3.5.1. Market Size and Forecast, By Type
      • 6.3.5.2. Market Size and Forecast, By Application
    • 6.3.6. France Amebocyte Lysate Market
      • 6.3.6.1. Market Size and Forecast, By Type
      • 6.3.6.2. Market Size and Forecast, By Application
    • 6.3.7. UK Amebocyte Lysate Market
      • 6.3.7.1. Market Size and Forecast, By Type
      • 6.3.7.2. Market Size and Forecast, By Application
    • 6.3.8. Italy Amebocyte Lysate Market
      • 6.3.8.1. Market Size and Forecast, By Type
      • 6.3.8.2. Market Size and Forecast, By Application
    • 6.3.9. Spain Amebocyte Lysate Market
      • 6.3.9.1. Market Size and Forecast, By Type
      • 6.3.9.2. Market Size and Forecast, By Application
    • 6.3.10. Rest of Europe Amebocyte Lysate Market
      • 6.3.10.1. Market Size and Forecast, By Type
      • 6.3.10.2. Market Size and Forecast, By Application
  • 6.4. Asia-Pacific
    • 6.4.1. Key Market Trends and Opportunities
    • 6.4.2. Market Size and Forecast, By Type
    • 6.4.3. Market Size and Forecast, By Application
    • 6.4.4. Market Size and Forecast, By Country
    • 6.4.5. Japan Amebocyte Lysate Market
      • 6.4.5.1. Market Size and Forecast, By Type
      • 6.4.5.2. Market Size and Forecast, By Application
    • 6.4.6. China Amebocyte Lysate Market
      • 6.4.6.1. Market Size and Forecast, By Type
      • 6.4.6.2. Market Size and Forecast, By Application
    • 6.4.7. Australia Amebocyte Lysate Market
      • 6.4.7.1. Market Size and Forecast, By Type
      • 6.4.7.2. Market Size and Forecast, By Application
    • 6.4.8. India Amebocyte Lysate Market
      • 6.4.8.1. Market Size and Forecast, By Type
      • 6.4.8.2. Market Size and Forecast, By Application
    • 6.4.9. South Korea Amebocyte Lysate Market
      • 6.4.9.1. Market Size and Forecast, By Type
      • 6.4.9.2. Market Size and Forecast, By Application
    • 6.4.10. Rest of Asia-Pacific Amebocyte Lysate Market
      • 6.4.10.1. Market Size and Forecast, By Type
      • 6.4.10.2. Market Size and Forecast, By Application
  • 6.5. LAMEA
    • 6.5.1. Key Market Trends and Opportunities
    • 6.5.2. Market Size and Forecast, By Type
    • 6.5.3. Market Size and Forecast, By Application
    • 6.5.4. Market Size and Forecast, By Country
    • 6.5.5. Brazil Amebocyte Lysate Market
      • 6.5.5.1. Market Size and Forecast, By Type
      • 6.5.5.2. Market Size and Forecast, By Application
    • 6.5.6. Saudi Arabia Amebocyte Lysate Market
      • 6.5.6.1. Market Size and Forecast, By Type
      • 6.5.6.2. Market Size and Forecast, By Application
    • 6.5.7. South Africa Amebocyte Lysate Market
      • 6.5.7.1. Market Size and Forecast, By Type
      • 6.5.7.2. Market Size and Forecast, By Application
    • 6.5.8. Rest of LAMEA Amebocyte Lysate Market
      • 6.5.8.1. Market Size and Forecast, By Type
      • 6.5.8.2. Market Size and Forecast, By Application

CHAPTER 7: COMPETITIVE LANDSCAPE

  • 7.1. Introduction
  • 7.2. Top Winning Strategies
  • 7.3. Product Mapping of Top 10 Player
  • 7.4. Competitive Dashboard
  • 7.5. Competitive Heatmap
  • 7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

  • 8.1. Lonza Group AG
    • 8.1.1. Company Overview
    • 8.1.2. Key Executives
    • 8.1.3. Company Snapshot
    • 8.1.4. Operating Business Segments
    • 8.1.5. Product Portfolio
    • 8.1.6. Business Performance
    • 8.1.7. Key Strategic Moves and Developments
  • 8.2. Charles River Laboratories
    • 8.2.1. Company Overview
    • 8.2.2. Key Executives
    • 8.2.3. Company Snapshot
    • 8.2.4. Operating Business Segments
    • 8.2.5. Product Portfolio
    • 8.2.6. Business Performance
    • 8.2.7. Key Strategic Moves and Developments
  • 8.3. Associates of Cape Cod Inc
    • 8.3.1. Company Overview
    • 8.3.2. Key Executives
    • 8.3.3. Company Snapshot
    • 8.3.4. Operating Business Segments
    • 8.3.5. Product Portfolio
    • 8.3.6. Business Performance
    • 8.3.7. Key Strategic Moves and Developments
  • 8.4. Xiamen Bioendo Technology
    • 8.4.1. Company Overview
    • 8.4.2. Key Executives
    • 8.4.3. Company Snapshot
    • 8.4.4. Operating Business Segments
    • 8.4.5. Product Portfolio
    • 8.4.6. Business Performance
    • 8.4.7. Key Strategic Moves and Developments
  • 8.5. Zhanjiang A&C Biological
    • 8.5.1. Company Overview
    • 8.5.2. Key Executives
    • 8.5.3. Company Snapshot
    • 8.5.4. Operating Business Segments
    • 8.5.5. Product Portfolio
    • 8.5.6. Business Performance
    • 8.5.7. Key Strategic Moves and Developments
  • 8.6. Genscript Technology Corporation
    • 8.6.1. Company Overview
    • 8.6.2. Key Executives
    • 8.6.3. Company Snapshot
    • 8.6.4. Operating Business Segments
    • 8.6.5. Product Portfolio
    • 8.6.6. Business Performance
    • 8.6.7. Key Strategic Moves and Developments
  • 8.7. Nelson Laboratories, LLC
    • 8.7.1. Company Overview
    • 8.7.2. Key Executives
    • 8.7.3. Company Snapshot
    • 8.7.4. Operating Business Segments
    • 8.7.5. Product Portfolio
    • 8.7.6. Business Performance
    • 8.7.7. Key Strategic Moves and Developments
  • 8.8. Thermo Fisher Scientific, Inc.
    • 8.8.1. Company Overview
    • 8.8.2. Key Executives
    • 8.8.3. Company Snapshot
    • 8.8.4. Operating Business Segments
    • 8.8.5. Product Portfolio
    • 8.8.6. Business Performance
    • 8.8.7. Key Strategic Moves and Developments
  • 8.9. Merck And Co., Inc.
    • 8.9.1. Company Overview
    • 8.9.2. Key Executives
    • 8.9.3. Company Snapshot
    • 8.9.4. Operating Business Segments
    • 8.9.5. Product Portfolio
    • 8.9.6. Business Performance
    • 8.9.7. Key Strategic Moves and Developments
  • 8.10. Microcoat Biotechnologie GmbH
    • 8.10.1. Company Overview
    • 8.10.2. Key Executives
    • 8.10.3. Company Snapshot
    • 8.10.4. Operating Business Segments
    • 8.10.5. Product Portfolio
    • 8.10.6. Business Performance
    • 8.10.7. Key Strategic Moves and Developments